(redirected from Immune rejection)
Also found in: Dictionary, Thesaurus, Medical, Financial, Encyclopedia, Wikipedia.
Related to Immune rejection: Organ rejection
References in periodicals archive ?
With these "humanized" mouse models, the biologists then tested a variety of immune suppressing molecules alone or in combination and discovered one combination that worked perfectly to protect cells derived from human embryonic stem cells from immune rejection.
However, once it is generally recognized that parthenogenetic cells have similar characteristics of embryonic stem cells and offer the potential to solve critical immune rejection issues - while not requiring the destruction of viable human embryos - we expect these cells to be increasingly used in government funded research to study ways of reducing human suffering and treating intractable human diseases.
A description of ISCO's human parthenogenetic stem cells and their potential ability to solve critical immune rejection problems was reported in ISCO's peer review paper published December 19, 2007 in the online edition of Cloning and Stem Cells Journal: http://www.
Answer: Parkinson's and motor neurone disease could be early targets for embryonic stem cell-based therapies, particularly if the problem of immune rejection is eliminated.
In all other cases, such nuclear transfer clones contain mitochondrial DNA, derived from the cytoplasm of the ovum, that is foreign to the patient, and that would cause immune rejection in patients if injected.
Drugs inducing beta cell regeneration may then be combined with therapies to block immune rejection of the newly formed cells, thereby restoring normal function to the pancreas gland.
The most common argument in support of cloning for stem cell rearch is that it will solve the immune rejection problem with stem cell transplantation because the patient will get back her own undifferentiated cells instead of transplanted stem cells from a stranger.
Therefore, we would not expect to see immune rejection of the cells or antibodies produced against the proteins.
These hESC-derived hematopoietic cells not only have potential application in hematopoietic transplantation therapies, but also could be used to prevent immune rejection of transplanted cells derived from hESCs, thereby potentially eliminating the need for immunosuppressive drugs or nuclear transfer technologies.
As a result, immune rejection will always set a limit on the utility of these cells in medical practice.
Livestock may be modified so that their organs don't induce immune rejection in humans and can therefore act as life-saving transplants.
This problem, called immune rejection, is common with transplants - even when the donor is human.